Topic Hub
8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 8 of 8 clinical reviews.
A physician-reviewed breakdown of CJC-1295's FDA regulatory status, compounding law, safety data, and what patients and prescribers need to know before using this growth-hormone secretagogue.
Read clinical reviewCJC-1295 has never received FDA approval. Review the available FAERS adverse event data, clinical trial safety findings, and the regulatory actions shaping access to this compounded GHRH analog.
Read clinical reviewCJC-1295 has never received FDA approval. Review the full regulatory timeline, clinical trial data from Teichman et al., compounding pharmacy status, and current legal standing of this GHRH analog.
Read clinical reviewCJC-1295 (modified GRF 1-29) has never received FDA or EMA approval. Learn its current regulatory classification, compounding pharmacy status, and safety profile across major jurisdictions.
Read clinical reviewA complete regulatory timeline of CJC-1295 modified GRF from 2020 through 2026, covering FDA bulk drug substance decisions, compounding pharmacy guidance, and safety communications.
Read clinical reviewCJC-1295 has never received FDA approval. This article covers its regulatory history, patent landscape, compounding legality under 503A/503B frameworks, and the clinical trial data that shaped its current status.
Read clinical reviewCJC-1295 has no FDA approval. Learn about its regulatory status, compounding pharmacy sourcing, clinical trial data, safety signals, and what next-generation GH secretagogues may replace it.
Read clinical reviewHow the FDA and EMA differ in their regulatory treatment of CJC-1295 (modified GRF 1-29), including approval status, compounding oversight, and safety signals.
Read clinical review